Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Summary of Contract Assets and Liabilities (Details)

v3.22.4
Revenue Recognition - Summary of Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 1,898 $ 1,738
Long-term pharma contract assets 31 236
Total pharma contract assets 1,929 1,974
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 800 109
Long-term pharma capitalized commissions 715 882
Total pharma capitalized commissions 1,515 991
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 7,557 5,192
Long-term pharma contract liabilities 19 917
Total pharma contract liabilities $ 7,576 $ 6,109